Session 2E: Early-Stage Diagnosis of Alzheimer’s Disease with the Use of Magnetic Nanostructures
Session Number
Session 2E: 2nd Presentation
Advisor(s)
Kirsten Viola, Northwestern University
Location
Room A113
Start Date
28-4-2017 10:00 AM
End Date
28-4-2017 11:15 AM
Abstract
One approach to image Alzheimer's disease (AD) pathology is by positron emission tomography (PET), using probes that target amyloid fibrils. However, PET is costly and limited in availability, and does not provide an early diagnosis of AD by focusing on amyloid fibrils. Furthermore, AP oligomers have been shown to correlate better with the pathogenesis of AD in comparison to amyloid fibrils; hence, AP oligomers are now considered the putative toxins responsible for the neuronal damage exhibited in AD. Similar to PET, other diagnostic methods have been developed to characterize AD pathology, such as functional magnetic resonance imaging, diffusion weighted imaging, structural imaging, and arterial spin labeling, which despite their accuracy, are invasive and not pragmatic for the early diagnosis of AD. In an attempt to establish a diagnostic method for early-stage AD, an investigation is occurring regarding the efficacy of a humanized antibody, ACUI 93, in conjunction with a mixed-metal nanoparticle probe to image AP oligomers and provide a definitive diagnosis of AD.
Session 2E: Early-Stage Diagnosis of Alzheimer’s Disease with the Use of Magnetic Nanostructures
Room A113
One approach to image Alzheimer's disease (AD) pathology is by positron emission tomography (PET), using probes that target amyloid fibrils. However, PET is costly and limited in availability, and does not provide an early diagnosis of AD by focusing on amyloid fibrils. Furthermore, AP oligomers have been shown to correlate better with the pathogenesis of AD in comparison to amyloid fibrils; hence, AP oligomers are now considered the putative toxins responsible for the neuronal damage exhibited in AD. Similar to PET, other diagnostic methods have been developed to characterize AD pathology, such as functional magnetic resonance imaging, diffusion weighted imaging, structural imaging, and arterial spin labeling, which despite their accuracy, are invasive and not pragmatic for the early diagnosis of AD. In an attempt to establish a diagnostic method for early-stage AD, an investigation is occurring regarding the efficacy of a humanized antibody, ACUI 93, in conjunction with a mixed-metal nanoparticle probe to image AP oligomers and provide a definitive diagnosis of AD.